1.86

1.64% 0.03

Kyverna Therapeutics Inc (KYTX)

Overview News Price History Discussions Forecast

Kyverna Therapeutics Inc stock is traded at $1.86, with a volume of 286.27K. It is up +1.64% in the last 24 hours and down -26.77% over the past month. Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Previous Close:

$1.83

Open:

$1.82

24h Volume:

286.27K

Relative Volume:

0.85

Market Cap:

$96.38M

Revenue:

Net Income/Loss:

$-110.66M

P/E Ratio:

-0.6007

EPS:

-3.0963

Net Cash Flow:

$-97.76M

1W Performance:

-0.53%

1M Performance:

-26.77%

6M Performance:

-67.08%

1Y Performance:

-90.90%

1-Day Range:

$1.78

$1.95

1-Week Range:

$1.78

$2.27

52-Week Range:

$1.78

$20.39

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Name

Kyverna Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(510) 626-8331

Address

5980 HORTON STREET, EMERYVILLE

Employee

119

Twitter

Next Earnings Date

Latest SEC Filings

KYTX's Discussions on Twitter

Compare KYTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYTX Kyverna Therapeutics Inc	1.86	96.38M	0	-110.66M	-97.76M	-3.0963
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-24	Initiated	UBS	Buy
Oct-09-24	Initiated	Rodman & Renshaw	Buy
Jul-03-24	Initiated	H.C. Wainwright	Neutral
Mar-04-24	Initiated	JP Morgan	Overweight
Mar-04-24	Initiated	Leerink Partners	Outperform
Mar-04-24	Initiated	Morgan Stanley	Overweight
Mar-04-24	Initiated	Wells Fargo	Overweight

View All

Kyverna Therapeutics Inc Stock (KYTX) Latest News

Apr 19, 2025

JPMorgan Chase & Co. Has $8.10 Million Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

Apr 19, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 19, 2025

Apr 18, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Franklin Resources Inc. - MarketBeat

Apr 18, 2025

Apr 17, 2025

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode - Bluefield Daily Telegraph

Apr 17, 2025

Notice to Long-Term Shareholders of Kyverna Therapeutics, - GlobeNewswire

Apr 17, 2025

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR)Grabar Law Office Is Investigating Claims - TradingView

Apr 17, 2025

Apr 16, 2025

Investigation announced for Long-Term Investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR.com

Apr 16, 2025

Apr 15, 2025

Robbins LLP Reminds Kyverna Therapeutics, Inc. Investors of the Pending Securities Fraud Class Action Against KYTX - marketscreener.com

Apr 15, 2025

Kyverna Therapeutics Files For Offering Of Up To $50 Mln Common Stock From Time To TimeSEC Filing - marketscreener.com

Apr 15, 2025

Apr 11, 2025

HC Wainwright Has Negative Outlook for KYTX Q1 Earnings - MarketBeat

Apr 11, 2025

Apr 08, 2025

HC Wainwright Cuts Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $4.00 - MarketBeat

Apr 08, 2025

Apr 07, 2025

KYTX stock plunges to 52-week low, touches $1.85 amid market rout - Investing.com Australia

Apr 07, 2025

KYTX stock plunges to 52-week low, touches $1.85 amid market rout By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 05, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Apr 05, 2025

Morgan Stanley Has Lowered Expectations for Kyverna Therapeutics (NASDAQ:KYTX) Stock Price - MarketBeat

Apr 05, 2025

Apr 03, 2025

Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - ACCESS Newswire

Apr 03, 2025

H.C. Wainwright cuts Kyverna Therapeutics price target to $4 - Investing.com Australia

Apr 03, 2025

KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025

KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025

H.C. Wainwright cuts Kyverna Therapeutics price target to $4 By Investing.com - Investing.com Canada

Apr 03, 2025

Apr 01, 2025

Kyverna Therapeutics price target lowered to $20 from $40 at Morgan Stanley - TipRanks

Apr 01, 2025

Mar 31, 2025

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT) - GlobeNewswire

Mar 31, 2025

Kyverna Therapeutics Advances CAR T-Cell Therapy Trials - MSN

Mar 31, 2025

Kyverna Therapeutics price target lowered to $12 from $13 at UBS - MSN

Mar 31, 2025

Kyverna Therapeutics (NASDAQ:KYTX) Announces Quarterly Earnings Results - MarketBeat

Mar 31, 2025

Mar 30, 2025

KYVERNA THERAPEUTICS Earnings Preview: Recent $KYTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 30, 2025

Mar 28, 2025

KYTX stock touches 52-week low at $2.2 amid sharp annual decline - Investing.com

Mar 28, 2025

Kyverna Therapeutics inks sales agreement with Jefferies By Investing.com - Investing.com Canada

Mar 28, 2025

Mar 27, 2025